eVetPractice vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud veterinary practice management covering records, scheduling, invoicing, and pharmacy for small-animal clinics. El Segundo CA; developed by Covetrus as the cloud-native complement to legacy AVImark;
About
eVetPractice is an El Segundo, California-based cloud-based veterinary practice management software that provides independent veterinary clinics with scheduling, electronic medical records, treatment tracking, invoicing, pharmacy management, and client communication in a single web-based platform. Developed by Covetrus, eVetPractice represents the company's cloud-native veterinary practice management offering alongside its legacy AVImark on-premise system, targeting practices ready to move to a browser-based system without the hardware and IT maintenance overhead of on-premise software. The platform is designed for small-animal general practices and emergency hospitals, with clinical templates and workflows appropriate for companion animal medicine.\n\neVetPractice's pharmacy management module is a notable capability, allowing veterinary practices to manage in-clinic medication dispensing, track controlled substance logs, and connect to online pharmacy fulfillment through Covetrus's online pharmacy network. This pharmaceutical connectivity aligns with Covetrus's broader strategy of integrating its animal health distribution and pharmacy businesses with its practice management software. Practices using eVetPractice can process prescription refill requests and manage client prescription histories within the same system used for scheduling and medical records, reducing the context-switching that comes with managing separate pharmacy and practice management platforms.\n\neVetPractice competes with Shepherd, Digitail, ezyVet, and the modernized versions of legacy systems in the cloud veterinary practice management market. The company's positioning within Covetrus gives it integration advantages with the broader Covetrus ecosystem including diagnostic imaging, laboratory connectivity, and prescription management, but also means its development roadmap is influenced by the priorities of a large animal health distributor rather than solely by independent veterinary practice needs. eVetPractice serves practices primarily in the United States with a focus on the independent practice segment.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.